AML, Adult Clinical Trial
Official title:
Clinical Study to Evaluate the Safety and Efficacy of iPSC NK Cells Targeting CLL1 in Patients With Relapsed/Refractory AML
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients with relapsed/refractory AML
Status | Recruiting |
Enrollment | 24 |
Est. completion date | August 31, 2026 |
Est. primary completion date | August 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. =18 years old. 2. Confirmed diagnosis of r/r AML 3. CLL1 expression is positive in AML blasts. 4. Eastern Cooperative Oncology Group (ECOG) performance status =1 and life expectancy greater than 12 weeks. 5. Adequate organ and marrow function, as defined below: 1. Blood creatinine (Cr) = 2 x ULN or calculated creatinine clearance (Cockcroft- Gault formula) = 50 mL/min; 2. Total bilirubin (TBIL) = 2 x the ULN; 3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN; 4. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) = 1.5 x ULN 6. Females of childbearing potential must have a negative serum pregnancy test. 7. Donor specific antibody (DSA) is negative: MFI <= 2000. 8. Provision of signed and dated informed consent form (ICF). Exclusion Criteria: 1. Allergic to drug used in this study. 2. Subjects received any antitumor therapy as follows, prior to first NK infusion: 1. Systemic steroid therapy within 3 days (except physiological replacement therapy); 2. Systemic antitumor therapy within 2 weeks or at least 5 half-lives, whichever is less; 3. Radiotherapy within 4 weeks; 4. Donor lymphocyte infusion within 6 weeks; 5. Intrathecal treatment within 1 week; 6. CAR-T therapy, CAR-NK therapy, or any other genetically modified cell therapy product within 6 months; 3. History of allogeneic stem cell transplantation. 4. Received the vaccine within 4 weeks prior to the first infusion and/or expected to require vaccination from the study period to 12 weeks after the last infusion. 5. Active central nervous system Leukemia. 6. Acute Promyelocytic Leukemia (APL). 7. History of other malignant tumors, except for those who have achieved complete remission more than 5 years after radical treatment without any signs of recurrence. 8. Active autoimmune diseases. 9. History of central nervous system disease or meningeal involvement such as epilepsy, paralysis, aphasia, stroke, etc. 10. Serious cardiovascular and cerebrovascular diseases: 1. Severe heart rhythm or conduction abnormalities, corrected QT interval (QTc)=480 ms; 2. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events within 6 months prior to first infusion; 3. New York Heart Association (NYHA) class II or above congestive heart failure or left ventricular ejection fraction (LVEF) <50% in color Doppler echocardiography; 4. Hypertension that cannot be controlled by drug. 11. Active pulmonary infection; SpO2 =90%; Pulmonary embolism, chronic obstructive pulmonary disease, or interstitial lung disease. 12. Uncontrolled bacterial, fungal, or viral infection. Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection. 13. History of substance abuse. 14. Toxicity induced by previous therapy not recovered to = grade 2(NCI-CTCAE v5.0). 15. Large surgical treatment within 4 weeks prior to first infusion, not including diagnostic biopsy. 16. Pregnant/breastfeeding women. 17. Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject. |
Country | Name | City | State |
---|---|---|---|
China | Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang University | Hangzhou Qihangene Biotech Co.,Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment-Emergent Adverse Events | Safety and Tolerability | 28 Days from first dose of iPSC NK cell infusion | |
Primary | Incidence of subjects with Dose Limiting Toxicities within each dose level cohort | Tolerability | 28 Days from first dose of iPSC NK cell infusion | |
Secondary | Determination of the pharmacokinetics (PK) of iPSC NK cells in peripheral blood | The PK of iPSC NK in peripheral blood will be reported as the relative percentage of product DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points | Up to approximately 2 years after last dose of iPSC NK cell infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
Not yet recruiting |
NCT06313437 -
Revumenib in Combination With 7+3 + Midostaurin in AML
|
Phase 1 | |
Terminated |
NCT04079738 -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
|
Phase 1/Phase 2 | |
Recruiting |
NCT06052813 -
A Study of BN104 in the Treatment of Acute Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT02986620 -
Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
|
||
Recruiting |
NCT05601466 -
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT06066905 -
A Study of Chidamide With AZA in MRD Positive AML After Transplant
|
N/A | |
Recruiting |
NCT05909501 -
Assessment of Geriatric Evaluations Impact on New AML Guidance
|
||
Terminated |
NCT04614636 -
FT538 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT06420063 -
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04128020 -
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
|
Phase 1 | |
Active, not recruiting |
NCT04749355 -
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
|
Phase 2 | |
Active, not recruiting |
NCT04755244 -
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
|
Phase 1/Phase 2 | |
Completed |
NCT03194685 -
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT03884829 -
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
|
Phase 1 | |
Active, not recruiting |
NCT05177731 -
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
|
Phase 3 | |
Not yet recruiting |
NCT06377579 -
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
|
||
Recruiting |
NCT05025098 -
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
|
Phase 2 | |
Not yet recruiting |
NCT06263387 -
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
|
||
Not yet recruiting |
NCT06188182 -
D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia
|